



SERVIZIO SANITARIO REGIONALE  
EMILIA-ROMAGNA  
Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"  
Istituto di Ricovero e Cura a Carattere Scientifico

ISTITUTO  
ROMAGNOLO  
PER LO STUDIO  
DEI TUMORI  
DINO AMADORI

# MYELOMAS

*Personalized Prognosis  
and Precision Medicine Approaches  
for Enhanced Patient Care  
in Multiple Myeloma*

**10<sup>th</sup> - 11<sup>th</sup> OCTOBER, 2025**

**📍 The Hive Hotel, ROME**

## **PRESIDENTS**

**Claudio Cerchione and Gerardo Musuraca**

## **HONORARY PRESIDENTS**

**Nicola Normanno**

## **SCIENTIFIC COMMITTEE**

**Claudio Cerchione, Delia Cangini,  
Michela Ceccolini, Sofia Cortesi,  
Alessandro Lucchesi,  
Giovanni Martinelli, Matteo Marchesini,  
Gerardo Musuraca, Davide Nappi,  
Sonia Ronconi, Alice Rossi**

Organizing Secretariat



Provider n. 2773

## Registration

Download the “PROEVENTI” app on your smartphone.



Login or create a new account

Enter the event pin: MYELOMAS25

You are now on the event page, click on **“REGISTRATION”** at the top left

### **The Conference has been accredited to the Italian Ministry of Health:**

Event n. 458081 Provider n. 2773

ECM Credits n. 12 for:

Medical Surgeon (interdisciplinary area), Biologist, Pharmacist, TSLB, Nurse

Training objective 3: Clinical documentation. Diagnostic and rehabilitation clinical-care pathways, care profiles - treatment profiles.


Each participant, to obtain ECM credits, must participate in at least 90% of the scientific work and complete the online ECM questionnaire with a total of 75% of correct answers.

Attendance will be registered via barcode reader.

**Participation at the event is free of charge, but registration is compulsory.  
The registration deadline is 10 Oct 2025**



## PROMOTED BY



**SERVIZIO SANITARIO REGIONALE  
EMILIA-ROMAGNA**

**Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"**  
**Istituto di Ricovero e Cura a Carattere Scientifico**

ISTITUTO  
ROMAGNOLO  
PER LO STUDIO  
DEI TUMORI  
DINO AMADORI

## PATRONAGE



**SIE**  
**Società Italiana  
di Ematologia**



# FACULTY

<b>BAHLIS</b> NIZAR	UNIVERSITY OF CALGARY
<b>BEILHACK</b> ANDREAS	UNIVERSITY OF WUERZBURG
<b>BOTTA</b> CIRINO	UNIVERSITA' DEGLI STUDI DI PALERMO
<b>BRUNO</b> BENEDETTO	AOU CITTA' DELLA SALUTE E DELLA SCIENZA - TORINO
<b>BUDA</b> GABRIELE	AZIENDA OSPEDALIERO-UNIVERSITARIA DI PISA
<b>CANGINI</b> DELIA	IRCCS IRST- MELDOLA (FC)
<b>CAVO</b> MICHELE	ALMA MATER STUDIOURUM UNIVERSITA' DI BOLOGNA
<b>CECCOLINI</b> MICHELA	IRCCS IRST - MELDOLA (FC)
<b>CELLINI</b> CLAUDIA	OSPEDALE S. MARIA DELLE CROCI - RAVENNA
<b>CERCHIONE</b> CLAUDIO	IRCCS IRST - MELDOLA (FC)
<b>CORTESI</b> SOFIA	IRCCS IRST - MELDOLA (FC)
<b>DERUDAS</b> DANIELE	OSPEDALE ARMANDO BUSINCO - CAGLIARI
<b>DESANTIS</b> VANESSA	UNIVERSITA' DI BARI ALDO MORO
<b>DIMOPOULOS</b> MELETIOS A.	UNIVERSITY OF ATHENS
<b>DURIE</b> BRIAN	CEDARS SINAI MEDICAL CENTER - LOS ANGELES
<b>GHOBRIAL</b> IRENE	DANA-FARBER CANCER INSTITUTE/HARVARD MEDICAL SCHOOL - BOSTON
<b>LEE HANS</b> CHARLES	SARAH CANNON RESEARCH INSTITUTE - NASHVILLE
<b>LONIAL</b> SAGAR	EMORY UNIVERSITY SCHOOL OF MEDICINE - ATLANTA
<b>LUCCHESI</b> ALESSANDRO	IRCCS IRST- MELDOLA (FC)
<b>MARCHESINI</b> MATTEO	IRCCS IRST - MELDOLA (FC)
<b>MARTINELLI</b> GIOVANNI	ALMA MATER STUDIOURUM UNIVERSITA' DI BOLOGNA
<b>MATEOS</b> MARIA VICTORIA	UNIVERSITY OF SALAMANCA
<b>MONTEFUSCO</b> VITTORIO	IRCCS ISTITUTO NAZIONALE DEI TUMORI - MILANO
<b>MOREAU</b> PHILIPPE	UNIVERSITY OF NANTES
<b>MUSURACA</b> GERARDO	IRCCS IRST - MELDOLA (FC)
<b>NAPPI</b> DAVIDE	IRCCS IRST - MELDOLA (FC)
<b>NERI</b> PAOLA	UNIVERSITY OF CALGARY
<b>NORMANNO</b> NICOLA	IRCCS IRST - MELDOLA (FC)
<b>RICHARDSON</b> PAUL	DANA-FARBER CANCER INSTITUTE/HARVARD MEDICAL SCHOOL - BOSTON
<b>RICHTER</b> JOSHUA	TISCH CANCER INSTITUTE, MOUNT SINAI - NEW YORK
<b>ROMANO</b> ALESSANDRA	UNIVERSITA' DEGLI STUDI DI CATANIA
<b>RONCONI</b> SONIA	IRCCS IRST - MELDOLA (FC)
<b>ROSSI</b> ALICE	IRCCS IRST - MELDOLA (FC)
<b>ROTONDO</b> FRANCESCO	OSPEDALE INFERMI DI RIMINI
<b>SCHJESVOLD</b> FREDRIK	OSLO MYELOMA CENTER
<b>SOLIMANDO</b> ANTONIO	UNIVERSITA' DI BARI ALDO MORO
<b>TERRAGNA</b> CAROLINA	IRCCS POLICLINICO SANT'ORSOLA - BOLOGNA
<b>ZAMBELLO</b> RENATO	SCUOLA DI MEDICINA E CHIRURGIA - PADOVA



# KEY INFORMATION

## VENUE

The Hive Hotel – Roma

Via Torino 6, Stazione Termini, 00184 Roma ,Italia

## INTERNET

WiFi is available in all areas.





# GENERAL INFORMATION

## LANGUAGE

The official language during the congress is English, therefore, all presentations will be given in English.

## CLIMATE

The average temperature is around 16–27 degrees.

## BANKING SERVICE

The official currency in Rome is the Euro. Foreign currencies can be exchanged at banks, which are usually open from Monday to Friday from 08:30 to 13:30.

## HOTEL INFORMATION

For hotel information and reservations please visit the Hotels & Groups Desk.

## TAXI

The single number to call a taxi is 060609

For other utilities on the taxi service, see [www.060608.it](http://www.060608.it)

The journey to/ from Fiumicino Airport: 48€

The journey to/ from Ciampino Airport: 30€



# PUBLIC TRANSPORT




From Termini Station, you can get to the hotel on foot in a few minutes, exiting the main exit, Piazza dei Cinquecento.

From here heading to the left and crossing the road at the traffic light, go to Via Massimo D'Azeglio and walk it for about 250 meters.

From here turn right on Via Torino and walk it for 20 meters.

Welcome to come!









10  
10.25

**08.30 – 09.00 WELCOME**

**C. Cerchione, G. Musuraca, N. Normanno**

**SESSION 1**

**NEW INSIGHTS INTO THE BIOLOGY OF PLASMA CELLS DISCRASIAS**

**Chairs: G. Martinelli, A. Romano**

**09.00 – 09.20: From research to the clinical practice: the milestones of Myeloma biology**

**A. Romano**

**09.20 – 09.40: Cellular circuitries in the extra medullary disease**

**A.G. Solimando**

**09.40 – 10.00: Unmasking novel biomarkers to sketch future trajectories in Multiple Myeloma therapy**

**V. Desantis**

**10.00 – 10.30: Coffee Break**

**SESSION 2**

**HOW TO STRATIFY THE RISK IN THE ERA OF ULTRA-NOVEL AGENTS**

**Chairs: C. Cerchione, M. Cavo, B. Durie, S. Lonial**

**10.30 – 11.00: What we have learnt from iSTOPMM?**

**B. Durie**

**11.00 – 11.30: MGUS: how to manage?**

**S. Lonial**

**11.30 – 12.00: Smoldering Myeloma: how to manage?**

**M.V. Mateos**

**12.00 – 12.30: Biology of pre-myelomas: what is changing?**

**I. Ghobrial**

**12.30 – 13.40: Lunch**

**Friday, Oct 10**

**SESSION 3**

**OPEN QUESTIONS: WHERE ARE WE GOING?**

Chairs: J. Richter, A.G. Solimando

**13.40 – 14.00: Building on Anti-CD38 regimens to optimize outcome**

**P. Richardson**

**14.00 – 14.30: Should we continue to transplant myeloma?**

**J. Richter**

**14.30 – 14.50: How I manage Transplant-ineligible patients**

**C. Cerchione**

**14.50 – 15.20: Coffee Break**

**SESSION 4**

**MANAGEMENT OF MULTIPLE MYELOMA - POST-FRONTLINE SETTING**

Chairs: M. Cavo, S. Lonial, V. Montefusco

**DEBATE: The evolving landscape of maintenance therapy**

**Referee: S. Lonial**

**15.20 – 15.40: Until progression M. Cavo**

**versus**

**15.40 – 16.00: Fixed duration/MRD-driven V. Montefusco**

**16.00 – 16.30: How to evaluate MRD and why?**

**C. Terragna**

**16.30: *Closing of Day 1* – C. Cerchione, G. Musuraca**





A 3D illustration of a blood clot, depicted as a dark, irregular, and textured mass. It is surrounded by numerous red blood cells, which are shown as smooth, biconcave discs in various shades of red. The background is a warm, orange-red gradient. The overall composition suggests a medical or biological theme, specifically focusing on blood coagulation.

**11**

**10.25**

**09.00 WELCOME TO DAY 2**

**C. Cerchione, G. Musuraca**

**SESSION 5**

**FROM GUIDELINES TO CLINICAL PRACTICE**

**Chairs: G. Musuraca, B. Durie, S. Lonial**

**09.00 – 09.20: Special Lecture: Allogenic stem cell transplantation in multiple myeloma and therapy: related myeloid neoplasms**

**B. Bruno**

**Special Lecture: EHA-EMN-IMWG Guidelines: What is changing?**

**09.20 – 09.50: Treatment in frontline setting P. Moreau**

**09.50 – 10.20: Treatment of relapsed/refractory patients M. Dimopoulos**

**10.20 – 10.40: Coffee Break**

**SESSION 6**

**NEW ERA OF IMMUNOTHERAPY**

**Chairs: C. Cellini, C. Cerchione, F. Rotondo**

**10.40 – 11.00: All about Bispecific antibodies and how to integrate in daily practice**

**C. Cerchione**

**11.00 – 11.20: All about CAR-T and how to integrate in daily practice**

**B. Bruno**

**11.20 – 11.40: Long term toxicities and infectious prophylaxis in Multiple Myeloma (including vaccinations)**

**C. Botta**

**11.40 – 12.00: Linking the biology to the clinical decisions in Smouldering and active Myeloma**

**N. Bahlis, P. Neri**

**Saturday, Oct 11**

**12.00 – 12.20: Lecture:** New mechanisms of disease resistance to T-cell based therapies

**P. Richardson**

**12.20 – 13.20: Lunch**

## **SESSION 7**

### **PARTICULAR SETTINGS AND SITUATIONS**

Chairs: D. Cangini, H.C. Lee, F. Schjesvold

**13.20 – 13.40: Extra medullary disease**

**D. Derudas**

**13.40 – 14.00: Diagnosis and management of amyloidosis**

**H.C. Lee**

**14.00 – 14.20: Diagnosis and management of plasma cell leukemia**

**F. Schjesvold**

## **SESSION 8**

### **NEXT STEPS IN PERSONALIZED MEDICINE IN MULTIPLE MYELOMA**

Chairs: M.Ceccolini, A. Lucchesi

**14.20 – 14.40: The role of combined imaging in Smoldering and Multiple Myeloma**

**A. Rossi**

**14.40 – 15.00: Gene expression profiling plus integrated multidisciplinary approach, to detect new risk adapted prognostic index in Multiple Myeloma (and SMM) – The GIMPI Project**

**M. Marchesini**

**SESSION 9**

**NOVEL AGENTS ON THE HORIZON**

Chairs: A.G. Beilhack, G. Buda, R. Zambello

**15.00 – 15.20: XPO-1 inhibition**

**G. Buda**

**15.20 – 15.40: Anti-BCMA**

**H.C. Lee**

**15.40 – 16.00: Peptide-drug conjugates**

**R. Zambello**

**16.00 – 16.30: **Lecture:** New and emerging targets**

**A.G. Beilhack**

**16.30: *Closing of Day 2 and See you next year***

**C. Cerchione, G. Musuraca**



## SCIENTIFIC RATIONALE

In the last decades, survival rates of Multiple Myeloma have been brilliantly improved thanks to the introduction of novel agents: patients diagnosed after 2010 have had higher rates of novel therapy use and better survival outcomes compared with those of earlier years. Most relevant therapeutic advances over the past decades has been the introduction of novel therapies, such as immune modifying agents (thalidomide and lenalidomide) and proteasome inhibitors (bortezomib), adopted with or without stem cell transplantation. Moreover, in the last few years, the MM therapeutic “toolbox” has improved further with the approval in new generation IMiD (pomalidomide), the monoclonal antibodies, daratumumab and elotuzumab, as well as the new-generation proteasome inhibitors, carfilzomib and ixazomib, waiting for introduction in daily practice of novel agents with new mechanism of action (Belantamab, CAR-T). At the same time, there is increasing understanding of MM tumor biology, creating the rationale for new combinations of drugs and new therapy development. Discovery of the associated cytogenetic abnormalities confirm the hypothesis that MM is a heterogeneous disease, suggesting that riskadapted therapies and individualizing treatment will further help improve patient management. The aim of this event is the discussion between international and national experts.



## SILVER



Johnson & Johnson




## BRONZE

AstraZeneca 

SANDOZ

sanofi



SERVIZIO SANITARIO REGIONALE  
EMILIA-ROMAGNA

Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"  
Istituto di Ricovero e Cura a Carattere Scientifico

ISTITUTO  
ROMAGNOLO  
PER LO STUDIO  
DEI TUMORI  
DINO AMADORI

# MYELOMAS

*Personalized Prognosis  
and Precision Medicine Approaches  
for Enhanced Patient Care  
in Multiple Myeloma*

graphic design: Mario Titone  
[info@mariotitone.com](mailto:info@mariotitone.com)